^
Association details:
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
Source:
Title:

The potential long-term comparative effectiveness of larotrectinib vs. lenvatinib or sorafenib for treatment of NTRK fusion-positive metastatic thyroid cancer

Published date:
04/12/2021
Excerpt:
...NTRK+ metastatic thyroid cancer patients (including both anaplastic and differentiated thyroid cancer patients) from the larotrectinib...Larotrectinib is estimated to be superior to sorafenib and lenvatinib in eligible advanced thyroid cancer patients.